Latest “Covid-19 vaccine” monitoring in one place: connection with adverse reactions still very evident; signs still of aversion in younger folk

In this article, two strands of ongoing “Covid-19 vaccine” (or vaccine product) monitoring are brought together (at least temporarily).

The first is the examination of the relation between the AstraZeneca and Pfizer products with MHRA Yellow Card reports and adverse reactions therein (source data). This examination has chiefly taken the form of a set of tables, where the percentage of doses that are associated with reports and reactions is recorded to notice a confirmation of a linkage: the more “vaccine” is dispensed, the more there are reports of adverse reactions; see previous reports for a fuller explanation, with the most recent to be found by following this link.

Incidentally, the fuller analysis mentioned in aforesaid article can be expected at a later date. In the meantime, developments have forced the introduction of a new table in our usual database: the MHRA have started to distinguish how much of the second dose is dispensed in the form either of the AstraZeneca or the Pfizer product. So, as well as the usual table for each manufacturer, looking at rates per first dose, there is now an additional one each that finds percentages using the sum of first and second doses.

There are two things to say about this: firstly, it was decided to keep tracking the rates per first dose, even though it’s a form of monitoring that becomes unreliable as more second doses are dispensed (and at some point, it won’t be continuable). However, as there is no telling from the MHRA data whether or not a report or reaction can be attributed to a first or second dose, it is worth keeping for the time being. The least that can be said about the effect of second doses is that in the case of the Pfizer product, they do seem to have an impact on the rate of association between all product administered, and reports and reactions. The same, however, cannot be said about the very dismal AstraZeneca equivalent.

The fifth table that the reader will find below is the usual complete summary, where all doses across both vaccines are accounted for. It is here where it can be seen that the accumulating percentage change (although there is no space explicitly for it on this particular table) continues to increase, once again denoting general confirmation of a link between the products and the reactions and reports.

It only remains to be said that although the Moderna product had now started to be dispensed in the UK, and reports of association with adverse reaction have already appeared on the Yellow Card system, the MHRA has no data regarding how many doses have been administered. This is why the product is omitted from this exercise at this stage.

Further to the previous bulletin on vaccine product recipiency at FBEL (to be found here), the newest data (source), now showing things [in England] as they stand up to 18th April, again confirms that there is no shortage of product this month, contrary to what the UK Government had previously and notoriously claimed. Again, lower numbers of first doses are mitigated by higher numbers of second doses – more than are required – so that the total number of doses administered in the most recent week (2,828,230) was greater again than the sum for the seven days before that (2,424,318).

Again, one can speculate that UK Government well knew that take-up for a first dose would hit a spot of difficulty when it started to be offered to people who, for instance, would like to have a baby, and so invented a lie to make an excuse for a loss of momentum. And one of the clues discovered in the previous bulletin that indicated that younger people were rejecting the vaccine product in greater numbers was the reversing percentage increase in take-up in the 50-54 age category. There was an appearance of the saturation point having been reached in this category and at a relatively low 88.2% of the total population in the demographic. This was low in contrast with the average of 94.8% in an over-50 super grouping (ranging all the way to 80 year olds and over). [The average percentage for 55s and over was 95.7]. A prediction made in the previous bulletin that no more than 90% of 50-54 year olds would receive even one dose of vaccine product looks to be being realised. The percentage increase rate has flat lined at 0.6%, with only 88.8% of 50-54 year-olds having had the procedure.

Moreover, it looks as if the entire over-50 super-grouping has now been saturated with what very likely represents a final percentage of 95%. According to the NHS’ own figures, it means that there are above one million people aged 50 years or more who won’t be having any vaccine. This is actually not a failure, by any means, for the movement to reject medical tyranny.

Of related interest is how only 59.3% of the super-grouping ranging from 16 to 49 (the one that the author belongs to†) has received at least one dose of vaccine product. The percentage increase of recipiency from last week to this actually went up from 3.6% to 7.5%, but it is still low. It might be argued that the reason why it wasn’t greater was because the vaccine wasn’t available, but this wouldn’t be true.

As mentioned above, the number of second jabs continues to outstrip the first by a huge margin, with  2,253,261 of the former having been given in the week to the 18th, with only 574,969 first doses being dispensed in the same period.

Again, as mentioned above, more second doses were dispensed than need to have been. By the 24th January, there had been 3,530,752 (first) jabs given to the 79-and-unders, and 2,261,407 to the over 80s. At the 18th April, an extra 2,424,504 more than the target figure (of second doses) had been given to the 79-and-unders (a total of 5,955,256), and an extra 100,367 to the 80-and-overs (total, 2,361,774). That total figure for the second doses, by the way, is not far off the number for the number of first doses given to the same demographic (2,700,543), so watch this space for an indication of how many have either died, got too ill, or refused so that the second jab could not be administered.

Just for the record, the target for second doses, set by the 24th January figure (of first doses administered), was surpassed in the week from the 4th to 11th April for 79-and-unders, yet again a week ahead of schedule. The target for the 80-and-overs was met as per expectation, using the twelve week interval, in the week to the 18th.

† To be perfectly clear, the author has not had a “Covid-19 vaccine”, and never will. [Update, 29th April: actually, this is the percentage for the 45-49 category (which retains the author)].